Trial Profile
Pilot Study on the Determination of Tumor Concentrations of Protein Kinase Inhibitors in Patients With Newly Diagnosed High-grade Glioma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Sunitinib (Primary) ; Vandetanib (Primary)
- Indications Glioma
- Focus Pharmacokinetics
- 06 Oct 2020 Planned End Date changed from 1 Jan 2021 to 1 Nov 2021.
- 06 Oct 2020 Planned primary completion date changed from 1 Dec 2020 to 1 Nov 2021.
- 28 Aug 2019 Planned End Date changed from 1 Jan 2019 to 1 Jan 2021.